NASDAQ:DWTX Dogwood Therapeutics (DWTX) Stock Price, News & Analysis $4.82 -0.20 (-3.98%) Closing price 04:00 PM EasternExtended Trading$4.83 +0.01 (+0.21%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Dogwood Therapeutics Stock (NASDAQ:DWTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Dogwood Therapeutics alerts:Sign Up Key Stats Today's Range$4.76▼$5.2050-Day Range$2.94▼$11.1352-Week Range$1.62▼$29.28Volume105,875 shsAverage Volume1.94 million shsMarket Capitalization$9.21 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingBuy Company OverviewDogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.Read More… Dogwood Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks34th Percentile Overall ScoreDWTX MarketRank™: Dogwood Therapeutics scored higher than 34% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingDogwood Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageDogwood Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Dogwood Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Dogwood Therapeutics are expected to grow in the coming year, from ($6.43) to ($4.57) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dogwood Therapeutics is -0.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dogwood Therapeutics is -0.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDogwood Therapeutics has a P/B Ratio of 0.98. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Dogwood Therapeutics' valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for DWTX. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDogwood Therapeutics does not currently pay a dividend.Dividend GrowthDogwood Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for DWTX. News and Social Media0.6 / 5News SentimentN/A Search InterestOnly 8 people have searched for DWTX on MarketBeat in the last 30 days. This is a decrease of -47% compared to the previous 30 days.MarketBeat Follows4 people have added Dogwood Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Dogwood Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.20% of the stock of Dogwood Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 9.05% of the stock of Dogwood Therapeutics is held by institutions.Read more about Dogwood Therapeutics' insider trading history. Receive DWTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dogwood Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address DWTX Stock News HeadlinesBrokers Set Expectations for DWTX Q1 EarningsApril 27, 2025 | americanbankingnews.comHC Wainwright & Co. Upgrades Dogwood Therapeutics (DWTX)April 24, 2025 | msn.comElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of collapse and built two of the most valuable companies in history. Now, he's sounding the alarm about America's $36 trillion debt time bomb that could destroy the fabric of our society.As head of the Department of Government Efficiency (DOGE) under President Trump, Musk is exposing just how bad things are...May 5, 2025 | American Hartford Gold (Ad)Dogwood receives Nasdaq confirmation of complianceApril 11, 2025 | markets.businessinsider.comDogwood Therapeutics, Inc. Receives Nasdaq Confirmation of ComplianceApril 11, 2025 | financialpost.comDogwood Therapeutics, Inc. Receives Nasdaq Confirmation of ComplianceApril 11, 2025 | globenewswire.comDogwood management to meet with MaximApril 9, 2025 | markets.businessinsider.comDWTX: Interim Data for Phase 2b Trial in 4Q25…April 5, 2025 | msn.comSee More Headlines DWTX Stock Analysis - Frequently Asked Questions How have DWTX shares performed this year? Dogwood Therapeutics' stock was trading at $2.49 on January 1st, 2025. Since then, DWTX stock has increased by 93.6% and is now trading at $4.82. View the best growth stocks for 2025 here. How were Dogwood Therapeutics' earnings last quarter? Dogwood Therapeutics, Inc. (NASDAQ:DWTX) issued its quarterly earnings data on Monday, March, 31st. The company reported ($6.29) EPS for the quarter, missing analysts' consensus estimates of ($1.49) by $4.80. When did Dogwood Therapeutics' stock split? Shares of Dogwood Therapeutics reverse split on the morning of Wednesday, October 9th 2024. The 1-25 reverse split was announced on Saturday, January 1st 2000. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. Who are Dogwood Therapeutics' major shareholders? Dogwood Therapeutics' top institutional shareholders include FNY Investment Advisers LLC (0.65%). How do I buy shares of Dogwood Therapeutics? Shares of DWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings3/31/2025Today5/05/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DWTX CIK1818844 Webwww.dwtx.com Phone(866) 620-8655FaxN/AEmployees5Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$10.00 Low Stock Price Target$10.00 Potential Upside/Downside+107.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($11.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,300,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-217.12% Return on Assets-172.06% Debt Debt-to-Equity RatioN/A Current Ratio1.71 Quick Ratio1.71 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.94 per share Price / Book0.97Miscellaneous Outstanding Shares1,911,000Free Float1,169,000Market Cap$9.20 million OptionableN/A Beta1.99 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:DWTX) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersWill May start the next "Great Depression?"You probably haven't heard about this yet... But this could be the biggest wealth building opportunity of t...Behind the Markets | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dogwood Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dogwood Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.